Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-9341 in advanced breast cancer
NCT06515470Phase 1Recruiting
- Sponsor
- Biotheryx
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BTX-9341 in breast cancer (3 arms), sponsored by Biotheryx. Primary endpoints: Safety and Tolerability of BTX-9341, Number of Participants With Dose Limiting Toxicities at 28 days and 3 more. Started Jul 2024; status: recruiting.
02
Drugs
BTX-9341
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06515470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515470.